Description
Indications
ADADX RAS GTPase , FDA KRAS G12C (NSCLC) , (ORR) (DOR) Description
Mécanisme d’action
12.1 Mecanisme d action Adagrasib KRAS G12C , KRAS G12C , KRAS , , KRAS Adagrasib KRAS G12C , KRAS G12C , Adagrasib ,Adagrasib KRAS G12C CRC
Pharmacologie
12 12.1 Mecanisme d action Adagrasib KRAS G12C , KRAS G12C , KRAS , , KRAS Adagrasib KRAS G12C , KRAS G12C , Adagrasib ,Adagrasib KRAS G12C CRC 12.2 Adagrasib - ,Adagrasib QTc
Precautions
5 Precautions • , , (2.3, 5.1) • QTc KRAZATI QTc QT , , ,
Interactions médicamenteuses
7 KRAZATI , (7) • CYP3A4 (7.1) • CYP3A4 , (7.1) • CYP3A4 CYP3A4 (7.2) • CYP2C9 CYP2D6 P-gp CYP2C9 CYP2D6 P-gp ,
